SK Biopharmaceuticals found joint venture with Glycyx

Published: 2018-01-10 16:18:51

Updated: 2018-01-10 16:18:51

SK Biopharmaceuticals(CEO Jung-Woo Cho) announced the company founded a joint venture to develop Relenopride as a rare nervous disease treatment with Glycyx Therapeutics Ltd. On the 7^th. SK Biopharmaceuticals and Glycyx will start its clinical development from the year of 2018 after founding the venture and attracting investments.

Glycix, a company founded by Dr. Lorin K. Johnson, a founder of...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.